POSB50 A Cost-Effectiveness Analysis of Rivaroxaban in Combination with Acetylsalicylic Acid (ASA) in Adult Patients with Coronary Artery Disease (CAD) or Symptomatic Peripheral Artery Disease (PAD) at High Risk of Ischaemic Events
Jan 1, 2022, 00:00
10.1016/j.jval.2021.11.323
https://www.valueinhealthjournal.com/article/S1098-3015(21)02118-5/fulltext
Title :
POSB50 A Cost-Effectiveness Analysis of Rivaroxaban in Combination with Acetylsalicylic Acid (ASA) in Adult Patients with Coronary Artery Disease (CAD) or Symptomatic Peripheral Artery Disease (PAD) at High Risk of Ischaemic Events
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(21)02118-5&doi=10.1016/j.jval.2021.11.323
First page :
Section Title :
Open access? :
No
Section Order :
11094